News | February 27, 2026
Novo Nordisk & Vivtex team up to revolutionize oral hiologics
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
The agreement will see the two companies jointly develop and commercialise premium nutraceutical ingredients in advanced transdermal delivery formats
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
Glucagon is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus
Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio
This expanded partnership helps Evonik to streamline its distribution model in Asia Pacific
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
In animal health, the products will be mainly targeting mastitis and production disorders, gastrointestinal tract diseases, reproductive disorders, ectoparasites, and skin injuries
Subscribe To Our Newsletter & Stay Updated
